Bolt Biotherapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 6.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.25M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembr...